New Medicines Australia code of conduct focuses on transparency and disclosure

1 October 2015

The new Medicines Australia Code of Conduct comes into effect from today, bringing in changes to transparency and self-regulation codes.

This, the 18th edition, aims to increase transparency and build consumer trust by bringing in rules around disclosing company payments to healthcare professionals such as educational support through airfares and accommodation. Member companies of trade group Medicines Australia will have to publicly report when a company pays a healthcare professional for their service or provides financial support to them.

Healthcare stakeholders have voiced their support for the changes. Tim James, chief executive of Medicines Australia, said: “The new Code is an important development in building on the established, trusted relationship between patients and healthcare professionals. A strong working relationship and ongoing knowledge exchange between the Australian innovative medicines industry and healthcare professionals are critical to better patient outcomes.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK